<DOC>
	<DOCNO>NCT02934152</DOCNO>
	<brief_summary>Background : Rebound acid hypersecretion acid-related symptom discontinuation proton-pump inhibitor report previous study . In patient concurrent gastro-esophageal reflux disease Helicobacter pylorus infection , whether eradication H. pylorus aggravate acid-related symptom discontinuation proton-pump inhibitor ( PPI ) remain elusive Objective : This study aim investigate incidence severity acid-related symptom discontinuation proton-pump inhibitor reflux patient receive H. pylorus eradication Expected result : The investigator find incidence severity acid-related symptom discontinuation proton-pump inhibitor reflux patient receive H. pylorus eradication</brief_summary>
	<brief_title>Symptom Assessment Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication</brief_title>
	<detailed_description>Background : Rebound acid hypersecretion acid-related symptom discontinuation proton-pump inhibitor report previous study . In patient concurrent gastro-esophageal reflux disease Helicobacter pylorus infection , whether eradication H. pylorus aggravate acid-related symptom discontinuation proton-pump inhibitor remain elusive Objective : This study aim investigate incidence severity acid-related symptom discontinuation proton-pump inhibitor reflux patient receive H. pylori eradication Patients method : Consecutive reflux patient document validated questionnaire ( GerdQ ) upper endoscopy enrol outpatient clinic . After determination H. pylorus status urea breath test ( UBT ) , positive H. pylorus infection randomize two group . Group A ( n=100 ) give early H. pylorus eradication triple therapy two week ; group B ( n=100 ) give rabeprazole 20 mg qd 4 week , follow H. pylorus eradication triple therapy two week . The investigator determine H. pylorus status urea breath test incidence severity acid-related symptom GerdQ 4 week H. pylori eradication . For patient negative H. pylorus infection ( n=200 ) , proton-pump inhibitor rabeprazole 20 mg qd give 8 week incidence severity acid-related symptom evaluate GerdQ 4 week discontinuation PPI . The impact H. pylorus infection H. pylori eradication time incidence severity acid-related symptom discontinuation proton-pump inhibitor analyze . Expected result : The investigator find incidence severity acid-related symptom discontinuation proton-pump inhibitor reflux patient receive H. pylorus eradication</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients typical reflux symptom ( heartburn and/or acid regurgitation ) validate standard questionnaire GerdQ.16 2 . Aged &gt; = 20 year old . 3 . Willing receive H. pylorus eradication therapy . Exclusion criterion : 1 . Symptomatic reflux patient high grade erosive esophagitis ( LA classification Grade C D ) Barrett 's esophagus document endoscopy . 2 . Symptomatic reflux patient history use PPI recent one month . 3 . Subjects know allergy PPI . 4 . Peptic ulcer disease 5 . Cancers esophagus , stomach , duodenum 6 . Esophageal gastric varix 7 . Active upper gastrointestinal bleeding within 7 day prior enrollment 8 . Status total subtotal gastrectomy 9 . Pregnancy 10 . Use anticoagulant antiplatelets within one week prior enrollment 11 . Subjects bleed tendency</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>Helicobacter pylorus</keyword>
</DOC>